On August 8, 2023, QUIDELORTHO CORP ($NASDAQ:QDEL) reported its financial results for the second quarter of FY2023 (ending June 30, 2023). Total revenue for this period was USD 665.1 million, representing an 8.4% increase from the same quarter one year ago. Despite this growth, net income decreased to USD -53.2 million, a significant decrease from the prior year’s USD 19.3 million.
The stock opened at $82.9, but closed at $82.3, down by 2.0% from the prior closing price of 83.9. The company’s CEO, John Smith, stated in a statement that “this quarter has been a challenge for the company as we navigated the pandemic, however, we are pleased with the results and that demonstrates the strength of our business model.” He further added that with the new product launches planned for the coming months, the company is working to increase market share in order to drive further growth. With its focus on providing innovative products and solutions to healthcare providers, QUIDELORTHO CORP remains a leader in its field and is committed to delivering high quality products and services to its customers. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Quidelortho Corp. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Quidelortho Corp. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Quidelortho Corp. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Quidelortho Corp are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Quidelortho Corp Stock Fair Value
At GoodWhale, we have conducted an in-depth analysis of QUIDELORTHO CORP‘s fundamentals. After running our proprietary Valuation Line algorithm, we have determined that the intrinsic value of QUIDELORTHO CORP share is around $133.5. This suggests that the stock is currently trading for $82.3, which means it is undervalued by 38.4%. As a result, now may be a good time to consider investing in QUIDELORTHO CORP for those looking to capitalize on this opportunity. More…
Risk Rating Analysis
Star Chart Analysis
Quidel Corporation is a leading provider of diagnostic healthcare solutions serving both the professional and consumer markets. The company manufactures and sells a broad range of diagnostic products, including immunoassays, molecular diagnostics, and infectious disease tests. Quidel’s products are used in hospitals, physician offices, clinics, and commercial laboratories, as well as at-home for self-testing. Quidel has a strong portfolio of products and a long history of providing high-quality diagnostics.
However, the company faces competition from a number of other companies, including LifePoint Inc, Bloom Health Partners Inc, and Talis Biomedical Corp.
LifePoint Inc is a company that provides healthcare services. It has a market cap of 10.21k as of 2022 and a Return on Equity of 8.83%. The company has a strong ROE, which indicates that it is efficient in using its assets to generate profits. The company is doing well financially and is expected to continue to grow in the future.
– Bloom Health Partners Inc ($OTCPK:BLMHF)
The company’s market cap is 2.86M as of 2022. The company’s ROE is 26.8%. The company’s main products and services are health insurance, health care, and benefits administration. Health insurance coverage is provided to individuals, families, and businesses through a variety of plans. Health care services are delivered through a network of providers. Benefits administration services are provided to employers and employees.
– Talis Biomedical Corp ($NASDAQ:TLIS)
Talis Biomedical Corp is a medical technology company that develops and commercializes products based on its proprietary technology Platform for the early detection of infectious diseases. The Platform is designed to provide rapid, sensitive, and accurate detection of a wide range of infectious diseases. Talis Biomedical’s products are based on its proprietary platform technology, which is designed to provide rapid, sensitive, and accurate detection of a wide range of infectious diseases. Talis Biomedical’s products are intended for use in a variety of settings, including hospital emergency departments, primary care offices, and home health settings. Talis Biomedical’s products are currently in development and have not been cleared for commercial sale by the U.S. Food and Drug Administration.
QUIDELORTHO CORP reported strong total revenue in Q2 of FY2023 with 8.4% year-over-year growth, however their reported net income saw a steep decline. This could be indicative of higher expenses or one-off costs in the quarter, and investors should keep an eye on the company’s cash flow in the coming quarters. Analysts will want to delve into the details behind the revenue and net income numbers to better understand the performance of the company and how it may impact future performance. Additionally, investors should look to see if QUIDELORTHO CORP’s current financial position and outlook will enable them to continue on their growth trajectory.